292 related articles for article (PubMed ID: 23057624)
1. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
[TBL] [Abstract][Full Text] [Related]
2. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
[TBL] [Abstract][Full Text] [Related]
4. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
[TBL] [Abstract][Full Text] [Related]
8. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
[TBL] [Abstract][Full Text] [Related]
9. Quantitative evaluation of the onset and longevity of the action of incobotulinumtoxinA by skin displacement analysis in the treatment of glabellar frown lines.
Proebstle TM; Chung G; Weissberg R; Pavicic T
J Drugs Dermatol; 2014 Sep; 13(9):1067-72. PubMed ID: 25226007
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials.
Jones D; Carruthers J; Narins RS; Coleman WP; Harrington L; Brandt FS; Cohen JL
Dermatol Surg; 2014 Jul; 40(7):776-85. PubMed ID: 25111351
[TBL] [Abstract][Full Text] [Related]
11. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
Sattler G; Callander MJ; Grablowitz D; Walker T; Bee EK; Rzany B; Flynn TC; Carruthers A
Dermatol Surg; 2010 Dec; 36 Suppl 4():2146-54. PubMed ID: 21134045
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines in Male Subjects: Post-Hoc Analyses From Randomized, Double-Blind Pivotal Studies.
Jones DH; Kerscher M; Geister T; Hast MA; Weissenberger P
Dermatol Surg; 2017 Nov; 43 Suppl 2():S235-S241. PubMed ID: 29064991
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study.
Kerscher M; Rzany B; Prager W; Turnbull C; Trevidic P; Inglefield C
Dermatol Surg; 2015 Oct; 41(10):1149-57. PubMed ID: 26359996
[TBL] [Abstract][Full Text] [Related]
14. Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
Shome D; Kapoor R; Khare S
J Cosmet Dermatol; 2019 Dec; 18(6):1635-1641. PubMed ID: 31135088
[TBL] [Abstract][Full Text] [Related]
15. A Prospective, Split-Face, Randomized, Double-Blind Study Comparing OnabotulinumtoxinA to IncobotulinumtoxinA for Upper Face Wrinkles.
Yeilding RH; Fezza JP
Plast Reconstr Surg; 2015 May; 135(5):1328-1335. PubMed ID: 25919246
[TBL] [Abstract][Full Text] [Related]
16. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.
Prager W; Bee EK; Havermann I; Zschocke I
Clin Interv Aging; 2013; 8():449-56. PubMed ID: 23650444
[TBL] [Abstract][Full Text] [Related]
17. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
[TBL] [Abstract][Full Text] [Related]
19. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
